| Autor: |
Gorse GJ; Division of Infectious Diseases, Saint Louis University Health Sciences Center, MO 63110-0250, USA., Rogers JH, Perry JE, Newman FK, Frey SE, Patel GB, Belshe RB |
| Jazyk: |
angličtina |
| Zdroj: |
Vaccine [Vaccine] 1995 Feb; Vol. 13 (2), pp. 209-14. |
| DOI: |
10.1016/0264-410x(95)93138-y |
| Abstrakt: |
As part of a phase I safety and immunogenicity trial of a vaccinia-expressed HIV-1 recombinant gp160 (rgp160) candidate vaccine, we measured serum and saliva antibody responses in low risk, uninfected volunteers. Six healthy adult volunteers received 50 micrograms doses of rgp160 vaccine adjuvanted in alum and deoxycholate at months 0, 1, 6, and 12. A 200 micrograms rgp160 immunization was given to four volunteers at 18 months. The vaccine induced anti-envelope glycoprotein IgG and IgA serum antibodies in all six volunteers. Saliva antibodies to envelope glycoprotein appeared in some volunteers at certain timepoints. Three volunteers appeared to transiently develop vaccine-induced secretory IgA antibody to envelope glycoprotein in whole saliva. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect